Trial Profile
An Open-label Safety Study to Assess the Multiple-dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray Applied Twice Daily for 28 Days in Patients With Moderate to Severe Plaque Psoriasis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 11 Jun 2021 Planned End Date changed from 31 Aug 2018 to 31 Jan 2018.
- 11 Jun 2021 Planned primary completion date changed from 31 Aug 2018 to 31 Jan 2018.
- 11 Jun 2021 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2017.